Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development.

Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development.

In quite a few diseases, drug resistance due to target variability poses a serious problem in pharmacotherapy. This is certainly true for HIV, and hence, it is often unknown which drug is best to use or to develop against an individual HIV strain. In this work we applied 'proteochemometric'...

Full description

Bibliographic Details
Main Authors: Gerard J P van Westen, Jörg K Wegner, Peggy Geluykens, Leen Kwanten, Inge Vereycken, Anik Peeters, Adriaan P Ijzerman, Herman W T van Vlijmen, Andreas Bender
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3223189?pdf=render

Internet

http://europepmc.org/articles/PMC3223189?pdf=render

Similar Items